Lanreotide

Background

Lanreotide is a synthetic cyclic octapeptide somatostatin analog developed following the discovery of endogenous somatostatin (somatotropin-release inhibiting factor) in the early 1970s.[12] It was designed to provide prolonged inhibition of growth hormone (GH) and other peptide hormones while improving metabolic stability and receptor selectivity relative to native somatostatin.[12] Lanreotide is structurally related to octreotide but differs in its amino acid sequence and physicochemical properties, including a marked propensity to self-assemble in aqueous environments.[11]

Lanreotide was initially developed in short‑acting formulations and later as long‑acting depot preparations (lanreotide SR and lanreotide Autogel/Depot) enabling administration every 4 weeks for chronic endocrine disorders.[12] The drug is marketed under the trade name Somatuline (Somatuline Autogel in the EU; Somatuline Depot in the US) and is classified pharmacologically as a somatostatin receptor ligand (SRL) or somatostatin analog.

Clinically, lanreotide is primarily used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP‑NETs), with additional antisecretory use in functional neuroendocrine syndromes such as carcinoid syndrome, although the latter is more extensively documented for octreotide.[8][12][13][14]

Mechanism of action

Lanreotide acts as a potent agonist at somatostatin receptors (SSTRs), particularly SSTR2 and SSTR5, which are G‑protein–coupled receptors widely expressed in pituitary somatotroph adenomas and many neuroendocrine tumors.[7][8][12] Binding to SSTRs activates inhibitory Gi/o proteins, leading to:

• Inhibition of adenylyl cyclase and decreased intracellular cAMP
• Opening of K⁺ channels and membrane hyperpolarization
• Inhibition of voltage‑gated Ca²⁺ channels and reduced Ca²⁺ influx

These events reduce hormone exocytosis from endocrine cells and exert antisecretory effects on GH, insulin, glucagon, gastrointestinal peptides, and vasoactive substances.[7][12]

In acromegaly, lanreotide suppresses pituitary GH secretion and consequently lowers hepatic insulin‑like growth factor‑1 (IGF‑1) production, which mediates most peripheral manifestations of the disease.[12] In neuroendocrine tumors, lanreotide both reduces secretion of bioactive amines and peptides and exerts antiproliferative effects, including cell cycle arrest, reduced angiogenesis, and pro‑apoptotic signaling, partly via modulation of MAPK and PI3K–Akt pathways.[3][7][13][14]

Lanreotide also shows a unique self‑assembly behavior, forming monodisperse hollow nanotubes (~24 nm diameter) in water; this supramolecular organization is driven by specific aromatic and hydrogen‑bonding interactions within the cyclic peptide and is exploited in its depot formulations.[11]

Evidence summary

Acromegaly

Lanreotide is one of two first‑generation SRLs (along with octreotide) that form the standard pharmacologic therapy for acromegaly.[12] Early and subsequent trials (primarily with lanreotide SR and Autogel) demonstrated:

• Significant reductions in GH and normalization of IGF‑1 in a substantial proportion of patients
• Tumor shrinkage or stabilization in many pituitary adenomas

A review of somatostatin agonists for acromegaly reported that lanreotide long‑acting formulations, administered every 4 weeks, achieved biochemical control (GH and IGF‑1 normalization) in a clinically meaningful subset of patients, comparable to octreotide LAR, although head‑to‑head randomized data are limited.[12] Reported response rates in pooled analyses generally range from ~30–60% for normalization of IGF‑1, depending on baseline severity and criteria.[12]

Neuroendocrine tumors and CLARINET

The CLARINET trial is the pivotal randomized study establishing the antiproliferative effect of lanreotide in well‑ or moderately differentiated, metastatic GEP‑NETs.[14]

• Design: Phase 3, randomized, double‑blind, placebo‑controlled trial of lanreotide Autogel 120 mg vs placebo every 28 days.[14]
• Population: 204 patients with nonfunctioning, somatostatin‑receptor–positive, grade 1–2 GEP‑NETs (pancreatic, midgut, hindgut, and of unknown origin).[14]
• Primary endpoint: Progression‑free survival (PFS).

Key outcomes:

• At 24 months, PFS was significantly prolonged with lanreotide; estimated PFS at 24 months was 65.1% with lanreotide vs 33.0% with placebo.[14]
• Hazard ratio for progression or death: 0.47 (95% CI 0.30–0.73), indicating a 53% risk reduction.[14]
• Benefit was consistent across primary tumor sites and liver tumor burden subgroups.[14]

Subsequent guideline updates and reviews emphasize CLARINET as the central evidence base for first‑line lanreotide in well‑differentiated metastatic GEP‑NETs, particularly nonfunctioning tumors.[3][13][14]

Real‑world GEP‑NET data

A prospective, non‑interventional US community oncology study (NCT02730104) evaluated lanreotide Depot in 99 adults with locally advanced (inoperable) or metastatic GEP‑NETs.[5]

• Follow‑up: 24 months.
• Outcomes: 24‑month PFS rate 73.7% (95% CI 63.1–81.7) and 24‑month overall survival 84.2% (95% CI 74.0–90.7).[5]
• Median time to disease progression was not reached due to the low number of progression events.[5]
• Safety findings were consistent with the known profile of lanreotide.[5]

Other neuroendocrine neoplasms

Lanreotide, along with other somatostatin analogs, is used off‑label or investigationally in other SSTR‑expressing neoplasms (e.g., pheochromocytoma and paraganglioma), based on mechanistic rationale and limited clinical evidence.[7] These indications rely predominantly on small series and extrapolation from GEP‑NET and acromegaly data, and robust randomized data are lacking.[7]

Preclinical and mechanistic studies

Extensive preclinical data demonstrate lanreotide’s capacity to inhibit hormone secretion, cell proliferation, and tumor growth in SSTR‑expressing models, though these data are largely summarized in reviews rather than single pivotal experiments.[3][7][12][13]

The molecular self‑assembly study by Valéry et al. elucidated how lanreotide forms stable nanotubes in aqueous solution, identifying key aromatic residues and hydrogen bonding patterns that drive packing and supramolecular structure; this behavior underpins its depot properties but is not directly tied to receptor pharmacology.[11]

Clinical and research uses

Approved indications (US/EU)

Based on regulatory documents and major guideline summaries:[8][12][13][14]

• Acromegaly
  • Treatment of acromegaly in patients who have had inadequate response to surgery and/or radiotherapy or for whom these modalities are not appropriate.
• Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs)
  • Treatment of adults with unresectable, well‑ or moderately differentiated, locally advanced or metastatic GEP‑NETs.

Although somatostatin analogs are standard for symptom control in functional NETs (e.g., carcinoid syndrome), regulatory labeling for lanreotide in some regions focuses on tumor control rather than explicit symptom control, and octreotide LAR remains the best‑documented agent for carcinoid syndrome–related flushing and diarrhea.[8][13][14]

Investigational and off‑label areas

Lanreotide and other SRLs are under ongoing investigation or off‑label use in:

• Other neuroendocrine neoplasms (e.g., pheochromocytoma, paraganglioma) based on SSTR expression.[7]
• Combination therapy with targeted agents (e.g., everolimus) or peptide receptor radionuclide therapy (PRRT) to enhance disease control in advanced NETs.[3][7]

Evidence in these settings is largely limited to phase 2 studies, small cohorts, and retrospective series; no completed large randomized trials equivalent to CLARINET are available for these indications.[3][7]

Dosing context

Lanreotide is supplied as a long‑acting, deep subcutaneous depot formulation (Autogel/Depot) that permits extended dosing intervals.[10][12][14]

Typical dosing regimens reported in the literature (not prescribing guidance):

• Acromegaly
  • Long‑acting lanreotide Autogel is commonly administered at doses of 60–120 mg by deep subcutaneous injection every 4 weeks, with dose adjustments based on GH and IGF‑1 levels and clinical response.[12]
• GEP‑NETs (CLARINET regimen)
  • Lanreotide Autogel 120 mg every 28 days by deep subcutaneous injection was used throughout CLARINET and forms the reference dosing regimen for the antiproliferative indication.[14]

Short‑acting lanreotide formulations and alternative dosing schedules have been studied historically but are less commonly used since the adoption of depot preparations.[12]

Dose selection and interval adjustment in practice depend on disease severity, biochemical markers, tolerance, and regional labeling and guidelines; dosing decisions require specialist clinical judgment and are not standardized beyond approved product information.

Safety profile

The adverse effect profile of lanreotide is broadly similar to that of other somatostatin analogs.[8][12][13][14] The most frequently reported reactions are gastrointestinal and metabolic.

Common adverse events (from clinical trials and post‑marketing data):

• Gastrointestinal: diarrhea, abdominal pain, nausea, vomiting, flatulence, and constipation.[12][13][14]
• Biliary: cholelithiasis and biliary sludge, reflecting inhibition of gallbladder motility and bile secretion.[12][13]
• Metabolic: alterations in glucose tolerance, including hyperglycemia or, less commonly, hypoglycemia, via modulation of insulin and glucagon secretion.[12]
• Injection‑site reactions: pain, nodules, induration, and rarely localized granulomatous inflammation; a case report described lanreotide acetate–induced granulomatous inflammation after surgery for a neuroendocrine tumor.[2]

In CLARINET, the safety profile was consistent with prior experience; diarrhea, abdominal pain, and cholelithiasis were among the most common treatment‑related adverse events.[14]

A retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) characterized the post‑marketing safety of lanreotide, confirming the expected pattern of gastrointestinal, hepatobiliary, and metabolic events, and highlighting rare but notable signals requiring further evaluation.[4]

Serious but less common events include:

• Gallstone‑related complications (cholecystitis, biliary colic)[12][13]
• Severe glucose dysregulation in susceptible individuals (e.g., pre‑existing diabetes)[12]
• Potential bradycardia or conduction abnormalities, especially in patients with underlying cardiac disease or concomitant bradycardia‑inducing drugs (primarily extrapolated from class data).[12]

Long‑term tolerability is generally favorable, and many patients remain on therapy for years when clinically indicated.[8][12][13][14]

Contraindications and cautions

Formal contraindications and cautions are defined in product labeling; based on class characteristics and trial experience:[8][12][13][14]

• Contraindications (class‑consistent):

  • Known hypersensitivity to lanreotide or excipients.

• Cautions:

  • Pre‑existing gallbladder disease (risk of gallstones and biliary complications).
  • Diabetes mellitus or impaired glucose tolerance (risk of glycemic destabilization).
  • Cardiac disease, especially bradycardia or conduction disorders, and concomitant beta‑blockers or other heart‑rate–lowering agents.
  • Potential interactions with drugs whose absorption may be affected by reduced gastrointestinal motility.

Regulatory status

Lanreotide (Somatuline Autogel/Depot) is an approved somatostatin analog in multiple regions, including the United States and European Union, for endocrine and neuroendocrine indications.[8][12][13][14]

• In the US, lanreotide Depot is approved for:

  • Treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
  • Treatment of adults with unresectable, well‑ or moderately differentiated, locally advanced or metastatic GEP‑NETs of the gastrointestinal tract and pancreas.

• In the EU, Somatuline Autogel has comparable approvals for:

  • Treatment of acromegaly (as primary medical therapy or adjunctive therapy).
  • Treatment of grade 1 and a subset of grade 2 GEP‑NETs that are unresectable or metastatic.

Lanreotide is classified as a somatostatin receptor ligand in endocrine and oncology guidelines, and its use is embedded in evidence‑based algorithms for acromegaly and GEP‑NET management, largely on the basis of CLARINET and accumulated clinical experience.[3][8][12][13][14]

Additional uses in other SSTR‑expressing tumors are generally investigational or off‑label and are not reflected in current core regulatory approvals.[7]